Navigation Links
Circassia's Short-Course House Dust Mite Allergy Treatment Achieves Significant Long-Term Symptom Reduction
Date:9/12/2013

OXFORD, England, September 12, 2013 /PRNewswire/ --

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful results from a phase II clinical study of its house dust mite allergy treatment (House Dust Mite-Synthetic Peptide Immuno-Regulatory Epitope [HDM-SPIRE] based on Circassia's ToleroMune® technology).  Patients who received four doses of the treatment over 12 weeks had significantly improved allergy symptoms one year after the start of the trial compared with placebo, meeting the study's long-term primary endpoint.  The HDM-SPIRE treatment was extremely well tolerated.  

"These results in house dust mite allergy are particularly exciting as they reflect the significant long-term improvements we achieved with a similar short course of our Cat-SPIRE allergy treatment," said Steve Harris, Circassia's Chief Executive.  "In the US, Europe and many other countries house dust mites are responsible for more allergies than any other allergen, causing year-round suffering for millions of people.  Reducing patients' symptoms over the long-term is an important goal, and these results demonstrate the potential of our ToleroMune® technology to revolutionise allergy therapy by achieving this with a simple short course of treatment."

The double-blind, randomized trial was conducted in Toronto, Canada, where 172 volunteers with confirmed house dust mite allergy received one of four treatment regimens or placebo.  Investigators measured patients' allergy symptoms when exposed to house dust mite allergens, at baseline and during the 12-month study.  Those who received a short course of four doses over 12 weeks had a significant improvement in their symptoms one year after starting the treatment compared with those on placebo (p=0.02).  All treatment regimens were well tolerated, with a safety profile similar to placebo.  Circassia has submitted the study results for presentation at a leading scientific conference.  

About house dust mite allergy

House dust mites are found widely throughout homes, in bedding, carpets, soft furnishings and clothing.  Allergy to proteins in the mites' droppings is extremely common, and often associated with asthma.  In the United States and Europe, approximately one-in-four people are sensitised to house dust mites, with more people having allergic responses than to any other common allergen.  House dust mite allergy is a perennial condition that can impact sufferers' education, work, quality of life and social activities.  

About ToleroMune® technology

Circassia is developing a range of allergy treatments based on its novel, proprietary ToleroMune® technology.  This uses rationally-designed molecules identified from common allergens (Synthetic Peptide Immuno-Regulatory Epitopes; SPIREs) to generate regulatory T cells to control allergic responses and induce immune tolerance.  Circassia has successfully completed a number of phase II studies with its house dust mite, ragweed and grass allergy therapies, and its cat allergy treatment entered phase III testing in October 2012.  

Clinical results show that short, simple courses of SPIRE allergy treatments can greatly reduce patients' allergic responses and improve symptoms over long periods, while proving extremely well tolerated.  As a result, SPIRE treatments offer major potential clinical benefits compared with existing therapies, and have significant market opportunities.  More than 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is valued at approximately $12 billion per year.  

About Circassia

Circassia was founded by a team of highly experienced biotechnology scientists and entrepreneurs.  The company is based in the UK on the Oxford Science Park, and its joint venture with McMaster University (Adiga Life Sciences Inc) is located in Hamilton, Canada.  Circassia's ToleroMune® technology was developed originally by scientists at Imperial College, London.  Having successfully completed five fundraising rounds, Circassia has raised approximately £105 million ($178 million) and is backed by a syndicate of world-class institutional investors, including Imperial Innovations and Invesco Perpetual.


Contacts
Steve Harris
CEO
Circassia
Tel: +44(0)1865-405560
http://www.circassia.co.uk

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241



'/>"/>
SOURCE Circassia
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sundberg Kicks Off National Expansion With Openings of New Headquarters, Logistically Centric Mega Warehouses
2. White House S&T advisor the Honorable Dr. John Holdren tours Naval Research Laboratory
3. West Wireless Health Institute Applauds House Passage of Bill to Streamline FDA Medical Device Approval Process, Expedite Mobile Medical App Guidance
4. Labcon Attends White House Business Council Forum on American Manufacturing Competitiveness
5. Home sweet lab: Computerized house to generate as much energy as it uses
6. Lighthouse Worldwide Solutions Ramps Production of NanoCount 30+ Liquid Particle Counters for High Purity Water Applications
7. House to Vote on Post-Sandy Mold Relief Fund Next Week; Dr Mold Network Comments Amount is Truly Needed by Hurricane Victims
8. Brain State Technologies to Host Open House and Demonstrate Their Revolutionary Technology
9. How to Check for Bed Bugs in Houses, Hotels and Offices - CheckForBedBugs.com Releases It's Official Easy-to-Follow Guide
10. The Pittsburgh Life Sciences Greenhouse Congratulates Dr. Paul L. Kornblith, M.D., on Being Named the 2013 recipient of the Schoemaker Award
11. How to Do Spring Cleaning the Healthy Way: DistinctBright Explores the Overlooked Dangers of Household Cleaning Products and offers Natural Cleaning Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... PRINCETON, N.J. , Dec. 8, 2016 /PRNewswire/ ... a late-stage biopharmaceutical company focused on developing and ... is an unmet medical need, announced today the ... trial with SGX942 (dusquetide), a first-in-class Innate Defense ... (OM) in head and neck cancer patients undergoing ...
(Date:12/8/2016)... Savannah River Remediation LLC group evaluated ... NT-MAX Lake & Pond Sludge and Muck ... conjunction with Hexa Armor/ Rhombo cover manufactured by ... Discharge Elimination System requirements. The Savannah ... of elevated pH levels, above 8.5, especially during ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, Inc. ... a Wonderware Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based ... “The System Integrator Partner certification gives customers confidence that our engineers are fully ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Avanade is ... Formula One teams in history, exploit biometric data in ... performance and maintain the competitive edge against their rivals ... Avanade has worked with Williams during ... of biometric data (heart rate, breathing rate, temperature and ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , ... today it has seen a third consecutive year of ... sensor technology in 2016 with a 360 percent increase ... year. This increase was driven by sales of its ... robust interest in its technology for hearables for fitness ...
(Date:12/2/2016)... PUNE, India , December 1, 2016 /PRNewswire/ ... Market by Authentication type (Fingerprint, Voice), Future Technology (Iris ... Vehicle), and Region - Global Forecast to 2021", ... be USD 442.7 Million in 2016, and is ... 2021, at a CAGR of 14.06%. ...
Breaking Biology News(10 mins):